The new ST Genesia analyser is designed to automate and standardise results for Thrombin Generation. For laboratories, this is a significant step forward for assisting with assessment of thrombotic and haemorrhagic risks in patients.
The Stago Group’s Thrombinoscope, Tcoag and Stago teams united to share their skills and expertise to work on this joint project, the ST Genesia.
ST Genesia is an automated analyser, based on the same principles as the CAT system, which measures thrombin generation. Designed to support clinical applications in the lab, the key difference between systems is that CAT’s main purpose is for research and development.
ST Genesia aims at standardising and automating the thrombin generation test in order to make it widely accessable and available for use in in-vitro diagnostics (IVD). ST Genesia is designed to add to the information usually provided by routine tests (TP, TCA, etc.) or specialised tests (Anti-Xa, ECA) and offer an improved assessment of thrombotic and haemorrhagic risks to improve patient care.
A range of reagents specifically developed for ST Genesia is available:
- STG-ThromboScreen: Thrombin generation assessment in patients who are likely to suffer from thrombophilia.
- STG-BleedScreen*: Thrombin generation assessment in patients with bleeding risk, such as haemophiliacs.
- STG-DrugScreen*: Assessment of the effect of anticoagulants on treated patients, which could be useful for people at risk of drug accumulation (impaired renal function, people over 75, etc.).
ST Genesia has been presented at ISTH, SSC, Club IIa, ST Genesia Expert Event, Symposium. The high attendance at Stago stands, numerous requests for demonstrations as well as the large number of attendees at Stago events are all indications of the keen interest of the scientific and medical community in this new system.
ST Genesia and STG-ThromboScreen are now CE marked and available to order. Don’t hesitate to get in touch with your Stago representative for more information.